DE05075889T1 - Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen - Google Patents

Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen Download PDF

Info

Publication number
DE05075889T1
DE05075889T1 DE05075889T DE05075889T DE05075889T1 DE 05075889 T1 DE05075889 T1 DE 05075889T1 DE 05075889 T DE05075889 T DE 05075889T DE 05075889 T DE05075889 T DE 05075889T DE 05075889 T1 DE05075889 T1 DE 05075889T1
Authority
DE
Germany
Prior art keywords
virus
human
similar
particles
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE05075889T
Other languages
English (en)
Inventor
Robert C. Rose
William Bonnez
Richard C. Reichman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE05075889(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by University of Rochester filed Critical University of Rochester
Publication of DE05075889T1 publication Critical patent/DE05075889T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Polynukleotid, das L1-Capsid-Protein von HPV-11 kodiert, wobei der untranslatierte 3'-Bereich der hieraus transkribierten mRNA die Sequenz AUUUA nicht enthält.

Claims (13)

  1. Polynukleotid, das L1-Capsid-Protein von HPV-11 kodiert, wobei der untranslatierte 3'-Bereich der hieraus transkribierten mRNA die Sequenz AUUUA nicht enthält.
  2. Polynukleotid, das L1-Capsid-Protein von HPV-11 kodiert, wobei der untranslatierte 3'-Bereich der hieraus transkribierten mRNA die Sequenz AUUUA in der Nachbarschaft des L1-Stoppcodons nicht enthält.
  3. Polynukleotid nach Anspruch 1 oder 2, bei dem die mRNA die Sequenz AUUUA nicht innerhalb von 30 Nukleotiden des Stoppcodons der L1-kodierenden Sequenz enthält.
  4. Expressionsvektor, der ein Polynukleotid nach Anspruch 1 oder 2 enthält.
  5. Expressionsvektor nach Anspruch 4, der ein Baculo-Virus-Expressions-Vektor ist.
  6. Wirtszelle, die einen Expressionsvektor nach Anspruch 4 oder 5 enthält.
  7. Wirtszelle, die den Vektor nach Anspruch 5 enthält, wobei die Wirtszelle eine Insektenzelle ist.
  8. Verfahren zur Herstellung eines dem menschlichen Papillomavirus ähnlichen Teilchens oder Capsomers, wobei das Verfahren das Kultivieren einer Wirtszelle nach Anspruch 6 oder 7 und das Gewinnen dieses virusartigen Teilchens oder Capsomers aus dieser Zelle umfasst.
  9. Verfahren nach Anspruch 8, bei dem das L1-Capsid-Protein von einer ein L1-Protein kodierenden Sequenz exprimiert ist, die ein Protein oder einen Proteinkomplex erzeugt, der immunologische und morphologische Merkmale besitzt, die denen eines nativen Papillomavirus ähnlich sind, wobei dieses Teilchen oder Capsomer in der Lage ist, Antikörper in menschlichen Seren zu erkennen, die von Personen stammen, von denen bekannt ist, dass sie mit einem homologen Virus infiziert sind.
  10. Verfahren nach Anspruch 8 oder 9, bei dem das virusähnliche Teilchen oder Capsomer gereinigt wird.
  11. Verfahren zur Herstellung eines Impfstoffes gegen menschliche Papillomaviren, wobei das Verfahren das Erhalten eines dem menschlichen Papillomavirus ähnlichen Teilchens oder Capsomers nach einem der Ansprüche 8 bis 10 und seine Kombination mit einem Adjuvans umfasst.
  12. Verfahren zur Herstellung einer Kombination von menschlichen Papillomaviren ähnlichen Teilchen, wobei das Verfahren das Herstellen eines dem menschlichen Papillomavirus ähnlichen Teilchens umfasst, das ein L1-Capsid-Protein von HPV-11 umfasst, gemäß dem Verfahren nach einem der Ansprüche 8 bis 10 und Kombinieren mit einem oder mehreren virusähnlichen Teilchen, die ein L1-Protein von einem oder mehreren verschiedenen menschlichen Papillomaviren umfassen.
  13. Verfahren zur Herstellung eines multivalenten Impfstoffes gegen menschliche Papillomaviren, wobei das Verfahren das Gewinnen einer Kombination von menschlichen Papillomaviren ähnlichen Teilchen gemäß Anspruch 12 und eine Kombination mit einem Adjuvans umfasst.
DE05075889T 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen Pending DE05075889T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US28517 1993-03-09
US20730994A 1994-03-07 1994-03-07
US207309 1994-03-07

Publications (1)

Publication Number Publication Date
DE05075889T1 true DE05075889T1 (de) 2006-10-05

Family

ID=26703787

Family Applications (9)

Application Number Title Priority Date Filing Date
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69435332T Expired - Lifetime DE69435332D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075889T Pending DE05075889T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen

Family Applications Before (6)

Application Number Title Priority Date Filing Date
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE69435332T Expired - Lifetime DE69435332D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen

Country Status (13)

Country Link
EP (3) EP1588713B1 (de)
JP (4) JPH08507685A (de)
AT (3) ATE492289T1 (de)
AU (3) AU688759C (de)
CA (1) CA2157932C (de)
DE (9) DE69435331D1 (de)
DK (2) DK1618888T3 (de)
ES (3) ES2263405T3 (de)
FR (1) FR11C0022I2 (de)
LU (3) LU91313I2 (de)
NL (3) NL300265I2 (de)
PT (2) PT1618888E (de)
WO (1) WO1994020137A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000084I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
PT809700E (pt) * 1994-10-07 2006-09-29 Univ Loyola Chicago Particulas semelhantes ao papilomavirus e proteinas de fusao, assim como metodos para a sua producao
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
EP0863982B1 (de) * 1995-11-15 2004-01-21 Merck & Co., Inc. Synthetische hpv11 virusartige partikel
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
ATE256734T1 (de) * 1996-10-04 2004-01-15 Merck & Co Inc Synthetische hpv16 virus-ähnliche partikel
DE69727830T2 (de) * 1996-12-09 2004-10-07 Merck & Co Inc Synthetische hpv-16 virusähnliche partikel
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE60143583D1 (de) * 2000-09-18 2011-01-13 Medimmune Llc In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
CA2457804C (en) 2001-08-13 2012-10-16 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2678736A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional il-2 - il-18 fusion proteins
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (en) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Protein l1 and protein e7 peptide-based composition for treating and preventing a human papillomaviral infection
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2008223951B2 (en) 2007-03-02 2014-03-27 Glaxosmithkline Biologicals S.A. Novel method and compositions
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
US9533035B2 (en) 2007-05-29 2017-01-03 Xiamen University Truncated L1 protein of human papillomavirus type 11
EP2154149B1 (de) * 2007-05-29 2019-07-10 Xiamen University Verkürztes l1-protein des humanen papillomavirus 6
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
EP2280728B1 (de) 2008-05-26 2016-03-02 Cadila Healthcare Limited Kombinationsimpfstoff gegen masern- und humanpapillom-virus
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
WO2010112533A1 (en) * 2009-04-03 2010-10-07 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3242135B1 (de) 2010-04-08 2020-07-01 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
CA2866582A1 (en) 2012-03-18 2013-09-26 Brigitte Desiree Alberte Colau Method of vaccination against human papillomavirus
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
US10962534B2 (en) 2016-02-22 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
BR112018073690B1 (pt) 2016-05-16 2022-05-24 Infectious Disease Research Institute Formulação contendo agonista de tlr e métodos de uso
EP3458028A1 (de) 2016-05-16 2019-03-27 Infectious Disease Research Institute Pegylierte liposomen und verfahren zur verwendung
CA3023271A1 (en) 2016-06-01 2017-12-07 Infectious Disease Research Institute Nanoalum particles containing a sizing agent
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
CA3141577A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
CN117222428A (zh) 2021-02-11 2023-12-12 葛兰素史克生物有限公司 Hpv疫苗生产
CA3266697A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
DE122007000084I1 (de) 1991-07-19 2008-03-27 Univ Queensland St Lucia Impfstoff gegen Humanes Papillomavirus (Typ 18)

Also Published As

Publication number Publication date
JP4486075B2 (ja) 2010-06-23
AU2007201005A1 (en) 2007-03-29
WO1994020137A1 (en) 1994-09-15
EP1618888B1 (de) 2011-01-05
JP2010099091A (ja) 2010-05-06
ES2263405T3 (es) 2011-04-20
PT1618888E (pt) 2011-04-08
JP2010148514A (ja) 2010-07-08
EP1588713B1 (de) 2010-12-22
ES2263406T1 (es) 2006-12-16
LU91391I2 (fr) 2008-02-14
AU2007201006B2 (en) 2010-07-01
DE05075369T1 (de) 2006-11-16
HK1082206A1 (en) 2006-06-02
JP5386392B2 (ja) 2014-01-15
CA2157932A1 (en) 1994-09-15
AU6443694A (en) 1994-09-26
ATE492289T1 (de) 2011-01-15
NL300309I2 (nl) 2008-03-03
LU91392I2 (fr) 2008-02-14
EP0688227B1 (de) 2005-05-25
DK0688227T3 (da) 2005-06-27
JP5306251B2 (ja) 2013-10-02
AU2007201005B2 (en) 2010-06-10
DK1618888T3 (da) 2011-04-04
DE122011100018I1 (de) 2011-11-17
LU91313I2 (fr) 2007-04-23
CA2157932C (en) 2011-10-11
FR11C0022I1 (de) 2011-05-08
DE122007000089I1 (de) 2008-03-27
DE69434383D1 (de) 2005-06-30
ES2263405T1 (es) 2006-12-16
ES2263406T3 (es) 2011-06-06
NL300265I2 (nl) 2008-05-01
NL300265I1 (nl) 2007-05-01
AU688759C (en) 2006-12-21
DE122007000014I1 (de) 2007-05-24
HK1082196A1 (en) 2006-06-02
EP0688227A4 (de) 1996-05-29
NL300309I1 (nl) 2008-02-01
AU2007201006A1 (en) 2007-03-29
EP1588713A1 (de) 2005-10-26
AU688759B2 (en) 1998-03-19
PT688227E (pt) 2005-10-31
JPH08507685A (ja) 1996-08-20
DE69435331D1 (de) 2011-02-03
DE69435332D1 (de) 2011-02-17
EP1618888A1 (de) 2006-01-25
ES2242955T3 (es) 2005-11-16
DE69434383T2 (de) 2005-11-24
DE122007000090I1 (de) 2008-03-27
NL300310I1 (nl) 2008-02-01
EP0688227A1 (de) 1995-12-27
ATE494005T1 (de) 2011-01-15
FR11C0022I2 (fr) 2012-08-03
ATE296111T1 (de) 2005-06-15
ES2242955T4 (es) 2010-04-12
JP2007075117A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
DE05075889T1 (de) Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen
DE69535249T2 (de) Rekombinantes Papillomavirus L1 Protein
DE69333859T2 (de) Sich selbst-zusammenbauende rekombinante hpv16 papillomavirus hüllproteine
DE69002325T2 (de) Pharmazeutische zusammensetzung zur verhütung oder heilung von durch den papillomavirus induzierten tumoren.
DE69327307T2 (de) Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit
CA2113712A1 (en) Papilloma virus vaccine
RU2003118436A (ru) Модифицированный вариант вируса коровьей оспы ankara
Fleagle et al. Humeral morphology of the earliest apes
CA2283462A1 (en) Vectors having enhanced expression and methods of making and uses thereof
WO1994011738A1 (de) Bestimmung von peptidmotiven auf mhc-molekülen
DE3650650T2 (de) Vakzin gegen Varicella Zoster Virus
DE69330238T3 (de) Verfahren zur Herstellung des Ectoproteins des Hepatitis-C-Virus
DE2555169C2 (de)
DE69933875T2 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
Fristrom et al. The preparative isolation of imaginal discs from larvae of Drosophila melanogaster
Bradley et al. Cyclic excretion of hepatitis A virus in experimentally infected chimpanzees: biophysical characterization of the associated HAV particles
DE3853672T2 (de) Nichtzurückschlagende RNS-Viren.
DE69635825T2 (de) Rekombinante virale pseudopartikel und deren verwendung als impfstoff oder als antitumorale wirkstoffe
DE60029327T2 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
Huger et al. Further studies on Polypoxvirus chironomi, an insect virus of the pox group isolated from the midge Chironomus luridus
WO1995030754A1 (de) Für ein peptid eines papillomvirus-hauptcapsid-proteins codierende dna und dessen verwendungen
DE69203950T2 (de) Rekombinanter Impfstoff gegen Marek's Krankheit.
EP0284791A1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
DE10055545A1 (de) Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
WO1999009177B1 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen